Original Article
Modern Pathology (2009) 22, 1361–1366; doi:10.1038/modpathol.2009.108; published online 24 July 2009
Differentiated rhabdomyomatous tumors after chemotherapy for metastatic testicular germ-cell tumors: a clinicopathological study of seven cases mandating separation from rhabdomyosarcoma
Jessica A Clevenger1, Richard S Foster2 and Thomas M Ulbright1
- 1Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA
- 2Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USA
Correspondence: Dr TM Ulbright, MD, Department of Pathology, Indiana University Medical Center, Clarian Pathology Laboratory, Room 4014, 350 W. 11th Street, Indianapolis, IN, 46202, USA. E-mail: tulbrigh@iupui.edu
Received 14 April 2009; Revised 26 May 2009; Accepted 26 May 2009; Published online 24 July 2009.
Abstract
To gain insight concerning prognosis, we investigated seven cases of post-chemotherapy retroperitoneal lymph-node dissections from patients with testicular germ-cell tumors that contained sizable nodules of differentiated skeletal muscle, but that lacked both a primitive cellular component and mitotic activity. The patients were 18–28 years old at the time of retroperitoneal lymph-node dissection. All had a previous non-seminomatous germ-cell tumor of the testis, five of which had a teratoma component. In one the testicular tumor had foci of embryonal rhabdomyosarcoma. The retroperitoneal lymph-node dissections were performed 0.2–4.7 years after orchiectomy, all following cisplatin-based chemotherapy, and contained rhabdomyomatous tumors that ranged from 0.8–5 cm. These consisted of nodular to diffuse aggregates of fetal-type rhabdomyocytes with central to peripheral nuclei and abundant, eosinophilic, fibrillary cytoplasm with occasional cross striations. Elongated myotubes with multiple nuclei in a common sarcoplasm occurred at least focally in all cases. Mild to moderate nuclear atypia, including nuclear enlargement and nucleolar prominence, was present, but mitotic activity, necrosis, and a primitive cellular component were absent. All but one retroperitoneal lymph-node dissection also contained other teratomatous elements. Follow-up in six patients showed three were disease free at 2.2–3.4 years; two developed recurrent teratoma at 1.3–3.7 years; and a sixth developed recurrent teratoma at 0.5 and 2 years, followed at 17 years by progressive tumor with elevated
-fetoprotein. No patient with available follow-up developed progressive sarcoma. We conclude that rhabdomyomatous tumors in retroperitoneal lymph-node dissection specimens after chemotherapy for metastatic testicular germ-cell tumors show clinical behavior similar to teratoma rather than rhabdomyosarcoma. We believe the most likely explanation for the finding of pure rhabdomyomatous tumors in this setting, a phenomenon sometimes termed 'cytodifferentiation,' is selective persistence of differentiated tumor cells because of chemotherapy.
Keywords:
testicular germ-cell tumor, rhabdomyomatous tumor, rhabdomyosarcoma, teratoma, retroperitoneum
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Management of advanced germ-cell tumors of the testis
Nature Clinical Practice Urology Review (01 May 2008)
Management of advanced germ-cell tumors of the testis
Nature Clinical Practice Urology Review (01 May 2008)
Nature Clinical Practice Urology Review (01 Jul 2005)
Nature Clinical Practice Urology Review (01 Jul 2005)
RESEARCH
Identification of IGFBP-6 as an effector of the tumor suppressor activity of SEMA3B
Oncogene Original Article

